{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-FQQY0PD2/720092a2-f0ed-4350-87f4-62e1a51881d3/PDF","dcterms:extent":"159 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-FQQY0PD2/b606b98e-0aac-46e9-b7e5-9075ddaa9e9d/TEXT","dcterms:extent":"20 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-FQQY0PD2","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2019","dc:creator":"Knez, Lea","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:70"},{"@xml:lang":"sl","#text":"str. 290-295"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:2048538737","URN:URN:NBN:SI:doc-FQQY0PD2"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"bolezni jeter"},{"@xml:lang":"sl","#text":"hepatitis C"},{"@xml:lang":"sl","#text":"interakcije med zdravili"},{"@xml:lang":"sl","#text":"jetrna ciroza"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Interakcije med zdravili pri bolnikih z okvaro jeter| Drug interactions in patients with liver diseases|"},"dc:description":{"@xml:lang":"sl","#text":"Zdravljenje z zdravili pri bolnikih z boleznimi jeter zahteva skrben premislek o možnih tveganjih in koristi zdravljenja. Ob odsotnosti podatkov o vplivu jetrne bolezni na farmakokinetiko in farmakodinamiko zdravil, še manj pa na interakcije med zdravili, je treba zdravljenje omejiti na nujno potrebna zdravila s prednostno izbiro kombinacij, ki so že uveljavljene v klinični praksi. Protivirusna zdravila v uporabi pri zdravljenju virusnega hepatitisa C imajo veliko tveganje za interakcije med zdravili, zato moramo ob vsakem predpisu zdravila preveriti in izključiti klinično pomembne interakcije med zdravili. Ob velikem vplivu sprememb delovanja jeter na farmakokinetiko zdravil je razsežnost farmakokinetičnih interakcij pri bolnikih z boleznimi jeter primerljiva in celo manjša kot pri bolnikih brez bolezni jeter, medtem ko je razsežnost farmakodinamičnih interakcij, ki poslabšajo simptome jetrne bolezni, večja"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-FQQY0PD2","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-FQQY0PD2"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-FQQY0PD2/720092a2-f0ed-4350-87f4-62e1a51881d3/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-FQQY0PD2/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-FQQY0PD2"}}}}